Dose-escalation Study of Graft-versus-host Disease Prophylaxis With High-dose Post-transplantation Bendamustine in Patients With Refractory Acute Leukemia

Trial Profile

Dose-escalation Study of Graft-versus-host Disease Prophylaxis With High-dose Post-transplantation Bendamustine in Patients With Refractory Acute Leukemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Bendamustine (Primary) ; Busulfan; Fludarabine
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Graft-versus-host disease; Leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top